Tri-Prime Gene 三元基因
11 significant filings since 31 May 2026: 2 on regulatory inquiry, 8 on share issue and 1 on guarantee or financial assistance. The latest, on 30 Jun 2026: 关于对北京证券交易所2025年年报问询函回复的公告.
自 31 May 2026 起有 11 份重大公告：regulatory inquiry 2 份、share issue 8 份、guarantee or financial assistance 1 份。最新一份（30 Jun 2026）：关于对北京证券交易所2025年年报问询函回复的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 诸海滨,车欣航 | Outperform 增持 | 2 Sep 2026 | 3 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。